Concepts of scaffold-based tissue engineering - The rationale to use solid free-form fabrication techniques

Journal of Cellular and Molecular Medicine

Volumn 11, Issue 4, 2007, Pages 654-669

  Hutmacher, D W ^a,b   Cool, S ^a,c  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^c INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

Author keywords

Composites; Growth factors; Heparan sulphate; Mesenchymal stem cells; Rapid prototyping; Scaffolds; Tissue engineering

Indexed keywords

BIOMATERIAL; HEPARAN SULFATE; SIGNAL PEPTIDE;

ANIMAL; CHEMISTRY; HUMAN; INSTRUMENTATION; METABOLISM; METHODOLOGY; REVIEW; SYNTHESIS; TISSUE ENGINEERING; WOUND HEALING;

ANIMALS; BIOCOMPATIBLE MATERIALS; HEPARITIN SULFATE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; TISSUE ENGINEERING; WOUND HEALING;

EID: 34548260849     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2007.00078.x     Document Type: Review

References (46)

1. Vacanti CA. The history of tissue engineering. J Cell Mol Med. 2006 10 : 569 76.
2. Hutmacher DW, Sittinger M, Risbud MV. Scaffoldbased tissue engineering: rationale for computer-aided design and solid free-form fabrication systems. Trends Biotechnol. 2004 22 : 354 62.
3. Bach AD, Arkudas A, Tjiawi J, Polykandriotis E, Kneser U, Horch RE, Beier JP. A new approach to tissue engineering of vascularized skeletal muscle. J Cell Mol Med. 2006 10 : 716 26.
4. Kneser U, Stangenberg L, Ohnolz J, Buettner O, Stern-Straeter J, Mobest D, Horch RE, Stark GB, Schaefer DJ. Evaluation of processed bovine cancellous bone matrix seeded with syngenic osteoblasts in a critical size calvarial defect rat model. J Cell Mol Med 2006 10 : 695 707.
5. Zhou Y, Chen F, Ho ST, Woodruff MA, Lim TM, Hutmacher DW. Combined marrow stromal cell-sheet techniques and high-strength biodegradable composite scaffolds for engineered functional bone grafts. Biomaterials. 2007 28 : 814 824.
6. Hollister SJ. Porous scaffold design for tissue engineering. Nat Mater. 2005 4 : 518 24.
7. Kain MS, Einhorn TA. Recombinant human bone morphogenetic proteins in the treatment of fractures. Foot Ankle Clin. 2005 10 : 639 50.
8. Govender S, Csimma C, Genant HK, Valentin- Opran A, Amit Y, Arbel R, Aro H, Atar D, Bishay M, Borner MG, Chiron P, Choong P, Cinats J, Courtenay B, Feibel R, Geulette B, Gravel C, Haas N, Raschke M, Hammacher E, Van Der Velde D, Hardy P, Holt M, Josten C, Ketterl RL, Lindeque B, Lob G, Mathevon H, McCoy G, Marsh D, Miller R, Munting E, Oevre S, Nordsletten L, Patel A, Pohl A, Rennie W, Reynders P, Rommens PM, Rondia J, Rossouw WC, Daneel PJ, Ruff S, Ruter A, Santavirta S, Schildhauer TA, Gekle C, Schnettler R, Segal D, Seiler H, Snowdowne RB, Stapert J, Taglang G, Verdonk R, Vogels L, Weckbach A, Wentzensen A, Wisniewski T. Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: a prospective, controlled, randomized study of four hundred and fifty patients. J Bone Joint Surg Am. 2002 84-A : 2123 34.
9. De Long WG, Jr., Einhorn TA, Koval K, McKee M, Smith W, Sanders R, Watson T. Bone grafts and bone graft substitutes in orthopaedic trauma surgery. A critical analysis. J Bone Joint Surg Am. 2007 89 : 649 58.
10. Cool SM, Nurcombe V. Heparan sulfate regulation of progenitor cell fate. J Cell Biochem. 2006 99 : 1040 51.
11. Bernfield M, Kokenyesi R, Kato M, Hinkes MT, Spring J, Gallo RL, Lose EJ. Biology of the syndecans: a family of transmembrane heparan sulfate proteoglycans. Annu Rev Cell Biol. 1992 8 : 365 93.
12. Kinsella MG, Irvin C, Reidy MA, Wight TN. Removal of heparan sulfate by heparinase treatment inhibits FGF-2-dependent smooth muscle cell proliferation in injured rat carotid arteries. Atherosclerosis. 2004 175 : 51 57.
13. Rapraeger AC, Krufka A, Olwin BB. Requirement of heparan sulfate for bFGF-mediated fibroblast growth and myoblast differentiation. Science. 1991 252 : 1705 08.
14. Safaiyan F, Kolset SO, Prydz K, Gottfridsson E, Lindahl U, Salmivirta M. Selective effects of sodium chlorate treatment on the sulfation of heparan sulfate. J Biol Chem. 1999 274 : 36267 73.
15. Guimond SE, Turnbull JE. Fibroblast growth factor receptor signalling is dictated by specific heparan sulphate saccharides. Curr Biol. 1999 9 : 1343 6.
16. McKeehan WL, Wang F, Kan M. The heparan sulfatefibroblast growth factor family: diversity of structure and function. Prog Nucleic Acid Res Mol Biol. 1998 59 : 135 76.
17. Zisch AH, Zeisberger SM, Ehrbar M, Djonov V, Weber CC, Ziemiecki A, Pasquale EB, Hubbell JA. Engineered fibrin matrices for functional display of cell membrane-bound growth factor-like activities: study of angiogenic signaling by ephrin-B2. Biomaterials. 2004 25 : 3245 57.
18. Hutmacher DW. Scaffolds in tissue engineering bone and cartilage. Biomaterials. 2000 21 : 2529 43.
19. Schantz JT, Lim TC, Ning C, Teoh SH, Tan KC, Wang SC, Hutmacher DW. Cranioplasty after trephination using a novel biodegradable burr hole cover: technical case report. Neurosurgery. 2006 58 : ONS-E176.
20. Zhou YF, Sae-Lim V, Chou AM, Hutmacher DW, Lim TM. Does seeding density affect in vitro mineral nodules formation in novel composite scaffolds? J Biomed Mater Res. A. 2006 78 : 183 93.
21. Rai B, Teoh SH, Hutmacher DW, Cao T, Ho KH. Novel PCL-based honeycomb scaffolds as drug delivery systems for rhBMP-2. Biomaterials. 2005 26 : 3739 48.
22. Cuevas P, de Paz V, Cuevas B, Marin-Martinez J, Picon-Molina M, Fernandez-Pereira A, Gimenez- Gallego G. Osteopromotion for cranioplasty: an experimental study in rats using acidic fibroblast growth factor. Surg Neurol. 1997 47 : 242 6.
23. McCracken M, Lemons JE, Zinn K. Analysis of Ti- 6Al-4V implants placed with fibroblast growth factor 1 in rat tibiae. Int J Oral Maxillofac Implants. 2001 16 : 495 502.
24. Iwaniec UT, Mosekilde L, Mitova-Caneva NG, Thomsen JS, Wronski TJ. Sequential treatment with basic fibroblast growth factor and PTH is more efficacious than treatment with PTH alone for increasing vertebral bone mass and strength in osteopenic ovariectomized rats. Endocrinology. 2002 143 : 2515 26.
25. Nakamura T, Hanada K, Tamura M, Shibanushi T, Nigi H, Tagawa M, Fukumoto S, Matsumoto T. Stimulation of endosteal bone formation by systemic injections of recombinant basic fibroblast growth factor in rats. Endocrinology. 1995 136 : 1276 84.
26. Pun S, Florio CL, Wronski TJ. Anabolic effects of basic fibroblast growth factor in the tibial diaphysis of ovariectomized rats. Bone. 2000 27 : 197 202.
27. Joyce ME, Roberts AB, Sporn MB, Bolander ME. Transforming growth factor-beta and the initiation of chondrogenesis and osteogenesis in the rat femur. J Cell Biol. 1990 110 : 2195 207.
28. Schmidmaier G, Wildemann B, Heeger J, Gabelein T, Flyvbjerg A, Bail HJ, Raschke M. Improvement of fracture healing by systemic administration of growth hormone and local application of insulin-like growth factor-1 and transforming growth factor-beta1. Bone. 2002 31 : 165 72.
29. Marie PJ. Fibroblast growth factor signaling controlling osteoblast differentiation. Gene. 2003 316 : 23 32.
30. Srouji S, Blumen feld I, Rachmiel A, Livne E. Bone defect repair in rat tibia by TGF-1 and IGF-1 released from hydrogel scaffold. Cell Tissue Bank. 2004 5 : 223 30.
31. Jackson RA, Kumarasuriyar A, Nurcombe V, Cool SM. Long-term loading inhibits ERK1/2 phosphorylation and increases FGFR3 expression in MC3T3-E1 osteoblast cells. J Cell Physiol. 2006 209 : 894 904.
32. Berscht PC, Nies B, Liebendorfer A, Kreuter J. Incorporation of basic fibroblast growth-factor into methylpyrrolidinone chitosan fleeces and determination of the invitro release characteristics. Biomaterials. 1994 15 : 593 600.
33. Westall FC, Rubin R, Gospodarowicz D. Brainderived fibroblast growth factor: a study of its inactivation. Life Sci. 1983 33 : 2425 9.
34. Caccia P, Nitti G, Cletini O, Pucci P, Ruoppolo M, Bertolero F, Valsasina B, Roletto F, Cristiani C, Cauet G, et al. Stabilization of recombinant human basic fibroblast growth factor by chemical modifications of cysteine residues. Eur J Biochem. 1992 204 : 649 55.
35. Babensee JE, McIntire LV, Mikos AG. Growth factor delivery for tissue engineering. Pharm Res. 2000 17 : 497 504.
36. Hunter MG, Avalos BR. Granulocyte colony-stimulating factor receptor mutations in severe congenital neutropenia transforming to acute myelogenous leukemia confer resistance to apoptosis and enhance cell survival. Blood. 2000 95 : 2132 7.
37. Xu RH, Peck RM, Li DS, Feng X, Ludwig T, Thomson JA. Basic FGF and suppression of BMP signaling sustain undifferentiated proliferation of human ES cells. Nat Methods. 2005 2 : 185 190.
38. Papy-Garcia D, Barbosa I, Duchesnay A, Saadi S, Caruelle JP, Barritault D, Martelly I. Glycosaminoglycan mimetics (RGTA) modulate adult skeletal muscle satellite cell proliferation in vitro. J Biomed Mater Res. 2002 62 : 46 55.
39. Blanquaert F, Saffar JL, Colombier ML, Carpentier G, Barritault D, Caruelle JP. Heparan-like molecules induce the repair of skull defects. Bone. 1995 17 : 499 506.
40. Meddahi A, Caruelle JP, Gold L, Rosso Y, Barritault D. New concepts in tissue repair: Skin as an example. Diabetes & Metabolism. 1996 22 : 274 8.
41. Logeart-Avramoglou D, Jozefonvicz J. Carboxymethyl benzylamide sulfonate dextrans (CMDBS), a family of biospecific polymers endowed with numerous biological properties: a review. J Biomed Mater Res. 1999 48 : 578 90.
42. Escartin Q, Lallam-Laroye C, Baroukh B, Morvan FO, Caruelle JP, Godeau G, Barritault D, Saffar JL. A new approach to treat tissue destruction in periodontitis with chemically modified dextran polymers. FASEB J. 2003 17 : 644 51.
43. Lafont J, Blanquaert F, Colombier ML, Barritault D, Carueelle JP, Saffar JL. Kinetic study of early regenerative effects of RGTA11, a heparan sulfate mimetic, in rat craniotomy defects. Calcif Tissue Int. 2004 75 : 517 25.
44. Berrada S, Amedee J, Avramoglou T, Jozefonvicz J, Harmand MF. Effect of a derivatized dextran on human osteoblast growth and phenotype expression. J Biomater Sci Polym Ed. 1994 6 : 211 22.
45. Luong-Van E, Grondahl L, Chua KN, Leong KW, Nurcombe V, Cool SM. Controlled release of heparin from poly(epsilon-caprolactone) electrospun fibers. Biomaterials. 2006 27 : 2042 50.
46. Luong-Van E, Grondahl L, Nurcombe V, Cool S. In vitro biocompatibility and bioactivity of microencapsulated heparan sulfate. Biomaterials. 2007 28 : 2127 36.